Point Mutation Cell Lines

ENCN
Home > Gene Editing Services > Stable Cell Lines >
CRISPR-U™ Cell Line
CRISPR-U™ (based on CRISPR/Cas9 technology), developed by Ubigene, is more efficient than general CRISPR/Cas9 in double-strand breaking, and CRISPR-U™ can greatly improve the efficiency of homologous recombination, easily achieve knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo. With CRISPR-U, Ubigene has successfully edit genes on more than 100 cell lines.
CRISPR/Cas9 recognizes the target sequence with gRNA, and guide Cas9 endonuclease to cut the upstream of PAM, resulting in the double-strand break (DSB) of the target site DNA. To repair the DSB, the cell uses its own DNA repair mechanism to add or delete or replace pieces of DNA sequences via Homology Directed Repair (HDR) or Non-Homologous End Joining (NHEJ).Close
CRISPR-U™ (based on CRISPR/Cas9 technology), developed by Ubigene, is more efficient than general CRISPR/Cas9 in double-strand breaking, and CRISPR-U™ can greatly improve the efficiency of homologous recombination, easily achieve
Urinary System

Human bladder carcinoma cell line (TCCSUP)
Human bladder carcinoma cell line (5637)
Human Bladder Transitional Cell Carcinoma Cell Line (T24)
Human Embryonic Kidney Cell Line(HEK293)
Human Embryonic Kidney Cell Line(293T)
Human prostate carcinoma cell line (22RV1)
Madin-Darby Canine Kidney Cell Line (MDCK)
Distal nephron cell line (Distal nephron cell line（JU4s）)

Blood and Lymphatic System

Mouse Macrophage Cell Line (RAW264.7)
Porcine Alveolar Macrophage Cell Line (3D4/21)
Human Monocytic Cell Line (THP-1)
Rat Basophil Leukemia Cell Line (RBL-2H3)
Human leukemia cell line (HL-60)
Human T lymphocyte cell line (Jurkat, Clone E6-1)
Human myelogenous leukemia cell line (K-562)
Human caucasian histiocytic lymphoma cell line (U-937)
Human Acute Non-B Non-T Lymphocytic Leukemia Cell Line (Reh)
Human B Cell Lymphoma Cancer Cell Line U2932

Respiratory System

Human Lung Cancer Cell Line (A549)
Human Lung Cancer Cell Line (Calu-1)
Human Lung Squamous Carcinoma Cell Line (NCI-H520)
Lewis lung carcinoma (LLC)
Human Lung Cancer Cell Line (SK-MES-1)
Human Lung Squamous Cell Carcinoma Cell Line NCI-H226
Human Non-small Cell Lung Carcinoma Cell Line (NCI-H1299)
Human Non-small Cell Lung Carcinoma Cell Line (HCC827)
Human Small Cell Lung Cancer Cell Line H69AR
Human Bronchial Epithelial Cell Line (BEAS-2B)
Human Bronchial Epithelial Cell Line (16HBE)
Human hypopharyngeal carcinoma cell line (FaDu)
Chinese hamster lung cells (V79)

Endocrine System

Human Breast Cancer Cell Line (MDA-MB-231)
Human Breast Cancer Cell Line (MDA-MB-468)
Human Breast Cancer Cell Line (MDA-MB-453)
Human Breast Cancer Cell Line (MDA-MB-436)
Human Breast Cancer Cell Line (ZR-75-1)
Human Breast Epithelial Cell Line (HBL-100)
Human Breast Cancer Cell Line (MCF7)
Mouse Breast Cancer Cell Line (4T1)
Human Pancreatic Carcinoma Cell Line (PANC-1)
Human Breast Cancer Cell Line (JIMT-1)
Human breast cancer cell line (MCF-7)
Human Breast Adenocarcinoma Cell Line (SK-BR-3)
Human Metastatic Pancreatic Adenocarcinoma Cell Line (AsPC-1)
Mouse Pancreatic Cancer Cell Line (Pan02)
Murine Breast Cancer Cell Line (E0771)
Human Pancreatic Carcinoma Cell Line (MIA PaCa-2)
Human prostate cancer cell line (PC3)
Human Prostate Cancer Cell Line (VCaP)
Mouse Acinar Pancreatic Cell Line (266-6)
Human pancreatic cancer cell line (BxPC-3)
Human Breast Adenocarcinoma Cell Line (T-47D)

Circulatory System

Rat Cardiac Myocytes (H9C2)
Mouse Cardiac Muscle Cell Line (HL-1)
Human Coronary Artery Endothelial Cell line (HCAEC)
Mouse Myoblast Cell Line (C2C12)

Digestive System

Human Colon Cancer Cell Line (HCT116)
Human Colon Cancer Cell Line (SW480)
Human Colon Cancer Cell Line (SW620)
Human Colon Cancer Cell Line (HT-29)
Human Colon Cancer Cell Line (LoVo)
Human colon carcinoma cell line (RKO)
Human caucasian colon adenocarcinoma cell line (COLO 205)
Murine Colorectal Carcinoma Cell Line (MC38)
Murine colorectal carcinoma cell line (CT26.WT)
Human colon adenocarcinoma cell line (DLD-1)
Human colorectal adenocarcinoma cell line (NCI-H716)
Human colorectal adenocarcinoma cell line (Caco-2)
Human colon carcinoma cell line (T84)
Human Liver Cell Line (L-02)
Human liver cancer cell line (Hep G2)
Human Hepatoma Cell Line (Hep 3B)
Human hepatocellular carcinoma cell line (HuH-7)
Human Hepatocellular Carcinoma Cell Line (SNU-387)
Human Hepatocarcinoma Cell Line (SMMC-7721)
Mouse Hepatoma Cell Line (H22)
Mouse Hepatoma Cell Line (Hepa 1-6)
Human hepatobiliary cancer cell line (RBE)
Human Gastric Cancer Cell Line (HGC-27)
Human Gastric Cancer Cell Line (SGC-7901)
Human Gastric Cancer Cell Line (MGC80-3)
Human gastric cancer cell line (AGS)
Human Esophageal Squamous Carcinoma Cell Line (KYSE-150)
Human Esophageal Squamous Carcinoma Cell Line (KYSE-30)
Human renal cell carcinoma cell line (786-o)
African green monkey kidney cell (Vero)
Human Renal Cell Carcinoma Cell Line (ACHN)

Skeleton, Articulus, Soft Tissue, Derma System

Human Osteosarcoma Cell Line (MG63)
Human bone osteosarcoma epithelial cell line (U-2 OS)
Human fibrosarcoma cell line (HT1080)
Human malignant melanoma cell line (A-375)
Human Melanoma Cell Line (M14)
Murine melanoma cell line (B16-F10)
Human Epidermoid Carcinoma Cell Line (A431)
Mouse myeloma cell line (Sp2/0-Ag14)
Mouse Skin Cancer Cell Line (SCC7)
Immortalized Ameloblastoma Cells (hTERT-AM)

Ocular, Otolaryngologic and Oral System

Rat Muller Cell Line (rmc-1)
Human Nasopharyngeal Carcinoma Cell Line (NPC-43)
Human Nasopharyngeal Carcinoma Cell Line (cne2z)
Human Nasopharyngeal Carcinoma Cell Line (CNE-1)

Brain and Nervous System

Human Neuroblastoma Cell Line (SK-N-SH)
Human Neuroblastoma Cell Line (SH-SY5Y)
Mouse neuroblastoma cell line (Neuro-2a)
Human Glioblastoma Cell Line (U251)
Rat Glioblastoma Cell Line (C6)
Mouse Glioblastoma Cell Line (GL261)
Mouse Microglial Cell Line (BV2)
Human glioblastoma cell line (U-87 MG)
Mouse Anterior Parietal Bone Cell Line (MC3T3-E1 Subclone 14)
Human Microvascular Endothelial Cell Line (hCMECD3)
Immortalize Human Microvascular Endothelial Cell Line (hCMEC/D3)
Mouse Hippocampal Neuron Cell Line (HT22)

Reproductive System

Human Cervical Carcinoma Cell Line (HeLa)
Human Cervical Carcinoma Cell Line (Hela 229)
Human Cervical Squamous Cell Line (SiHa)
Mouse Embryonic Fibroblasts (NIH/3T3)
Chinese Hamster Ovary Cell Line (CHO-K1)
Human Ovarian Cancer Cell Line (SK-OV-3)
Human Ovarian Cancer Cell Line (OVCAR3)
Human Choriocarcinoma Cell Line (BeWo)
Human Ovarian Cancer Cell Line (CAOV3)
Human Trophoblast Cell Line (HTR-8/SVneo)
Mouse Pituitary Gonadotrope Cell Line (Lbetat2)
Mouse Testicular Stromal Cell Line (TM3)

Technical advantage
CRISPR-U:10X efficiency gene-editing

Exclusive innovation, 10 times more efficient in gene-editing.

100 types of knockin cell line

Successfully edit genes on more than 100 types of cell lines.

KO/PM/ KI

Easily generate knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo.

100% mutation guarantee

CRISPR-U™ offers a 100% mutation guarantee. No mutation, no charge!

Point Mutation Cell Lines
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC. A) Genomic sequence surrounding the mutation site: mutated nucleotide (T, red); sgRNA recognition site containing 20 bp (yellow); CRISPR cutting site between the 17th and 18th bp (bold); forward and reverse primers (pink). B) ssODN with 120 bp, 60 bp upstream and 60 bp downstream the mutation site containing the WT nucleotide (C, green).
Point mutation Strategy
Point Mutation Cell Line
Work Flow and Validation
Work Flow and Validation
Case Study
The A79V mutation of PSEN1 gene can cause Alzheimer's disease. Somatic cells of patients with Alzheimer's disease are induced into pluripotent stem cells (iPSCs), and then the mutant gene is modified by replacing the point mutation with a wild-type sequence. By studying the iPSC of patients and the modified iPSC, we can know the effect of the mutation on cell phenotype, so as to further study the pathological effect of the mutation.
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC.
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC.
A) Genomic sequence surrounding the mutation site: mutated nucleotide (T, red); sgRNA recognition site containing 20 bp (yellow); CRISPR cutting site between the 17th and 18th bp (bold); forward and reverse primers (pink).
B) ssODN with 120 bp, 60 bp upstream and 60 bp downstream the mutation site containing the WT nucleotide (C, green).
Work Flow and Validation
B. Sequencing of exon 4 of the PSEN1 gene in hiPSCs.
A) Heterozygous c.236C>T substitution in the mother line previously published.
B) Successful correction of the point mutation (T>C).
Reference：
Fukuda, N., Senga, Y., & Honda, S. (2019). Anxa2‐and Ctsd‐knockout CHO cell lines to diminish the risk of contamination with host cell proteins. Biotechnology progress, e2820.

Contact us✖

* How would you like us to contact you?
Our Solution Specialists will contact you within 2 business days. Of course, you can also tell us when you would like to be contacted:
 Search
 Email
 Recommendations from others
 Social media
 Other
×

Subscribe Us

By subscription, you consent to allow Ubigene Biosciences to store and process the information provided above to deliver the latest news, research spotlight, and promotions. You can unsubscribe from these communications at anytime.
WhatsApp: +86 153 6067 3248
TEL: +86 153 6067 3248 (Int'l)
US Toll free: 855 777 3210
EU Toll free: 800 3272 9252
Korea Toll free: 001 800 3272 9252

Gene Editing Services

EZ-editor™ Products

Copyright © 2024 Ubigene. All rights reserved.
×

Search documentation

Literature:

Name: *

Company: *

Telephone: *

Email:

Notes: After submitting the order, we will contact you as soon as possible.

request now